Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.62 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 11/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512765 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL3514771 | 0.86 | PIK3CA (0.57) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL3514332 | 0.85 | TNF (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL12989736 | 0.85 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL12990063 | 0.84 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL3513244 | 0.84 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL14013654 | 0.84 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL3512456 | 0.82 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL3512133 | 0.78 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CBPIK3CGTNF | |
| SCHEMBL3512132 | 0.78 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CBPIK3CGTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | PIK3CA 2/4885PIK3CD 4/4885PIK3CB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.